Alzheimer's Disease & Dementia
An Introduction to Alzheimer's Disease & Dementia
Major advances in the understanding of the pathogenesis of Alzheimer’s disease (AD), the most common form of dementia, have occurred over recent years, but the need for truly disease-modifying therapies remains. Novel pharmacotherapy strategies under investigation include the repurposing of medications used to treat non-AD illnesses and multi-target-directed ligands, offering promise in this challenging treatment landscape.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Alzheimer's Disease & Dementia Content
James E Galvin, AAIC 2021: Aducanumab for the Treatment of Alzheimer’s Disease
touchNEUROLOGY joins Prof James Galvin (University of Miami Miller School of Medicine, Miami, FL, USA) to discuss aducanumab for the treatment of Alzheimer’s disease, and what this recent accelerated approval might mean for future potential treatments. Questions 1. Why has the recent FDA accelerated approval of aducanumab for Alzheimer’s disease been so controversial? (00:13-02:00) 2. […]
Gabriel A de Erausquin, AAIC 2021: The Alzheimer’s Association-led Global SARS-CoV-2 Consortium
touchNEUROLOGY joins Gabriel de Erausquin (UT Health San Antonio, TX, USA) at AAIC 2021 to discuss the Alzheimer’s Association-led Global SARS-CoV-2 Consortium and the links between long-term cognitive dysfunction, acceleration of Alzheimer’s symptoms and COVID-19. Questions Could you tell us a little about the Alzheimer’s Association-led global SARS-CoV-2 consortium? (00:30-02:07) What were the aims and […]
Jeffrey Cummings, AAIC 2021: Aducanumab for the Treatment of Early Alzheimer’s Disease
touchNEUROLOGY joins Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) at AAIC 2021 to discuss the EMERGE clinical trial findings and what this means for the use of aducanumab on the treatment of patients with Alzheimer’s disease. The abstract entitled “Item-level analysis of clinical measures in patients with early symptomatic Alzheimer’s disease following treatment […]
Marwan Sabbagh: Approval of Aducanumab for Alzheimer’s Disease
It was a great pleasure to meet up with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Las Vegas, NV, USA), to discuss the recent approval of aducanumab for Alzheimer’s Disease. Aducanumab was granted accelerated approval on June 7 2021, by the U.S. Food and Drug Administration (FDA). Questions: Could you give us a brief […]
Claudia Trenkwalder, EAN 2021: REM Sleep Behaviour Disorder and Neurodegeneration
touchNEUROLOGY was joined by Prof. Claudia Trenkwalder (Paracelsus-Elena-Hospital, Kassel Germany, University Medical Center, Goettingen, Germany) to discuss her EAN presentation looking into REM Sleep Behaviour Disorder and the connection with neurodegeneration. The abstract entitled: ‘REM Sleep Behaviour Disorder (RBD): future implications for neurodegenerative disease’ was presented at the 7th Congress of the European Academy of […]
Ivana Rosenzweig, Sleep and Breathing 2021: The Link Between Sleep Apnoea and Dementia
We were delighted to speak with Dr Ivana Rosenzweig (Sleep and Brain Plasticity Centre, King’s College London, London, UK) around her talk on the ‘Link between sleep apnoea and dementia: the neuroimaging perspective‘, which was presented at the virtual 2021 Sleep and Breathing Conference, 16-17 April, 2021. Questions What is known about the relationship between […]
Gregory Branigan, AAN 2021: Impact of Estrogen Therapies on Alzheimer’s Disease Pathways
We were delighted to meet with Gregory Branigan (University of Arizona, AZ, USA) to discuss the impact of estrogen therapies on Alzheimer’s disease pathways. The abstract entitled: ‘Breast Cancer Therapies Reduce Risk of Alzheimer’s Disease and Dementia: Clinic to Bench Translation’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021. Questions: What […]
Jeffrey Cummings, AAN 2021: BAN2401 Effects On Brain Amyloid And ARIA-E Findings
touchNEUROLOGY caught up with Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) one of our Editorial Board Members, to discuss BAN2401’s use in early stage Alzheimer’s Disease, and Amyloid Related Imaging Abnormalities (ARIA)-E alterations and their utility in amyloid-modifying trials. The abstract entitled: ‘Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings […]
Jeffrey Cummings, AAN 2021: Phase 2b Study of BAN2401 in subjects with Early Alzheimer’s Disease
touchNEUROLOGY caught up with Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) one of our valued Editorial Board Members, to discuss the open-label extension of the Phase 2b Study (BAN2401-G000-201) in subjects with early Alzheimer’s Disease. The abstract entitled: ‘Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!